2seventy bio, Inc. (TSVT)

USD 2.97

(-7.48%)

Market Cap (In USD)

153.21 Million

Revenue (In USD)

100.38 Million

Net Income (In USD)

-217.57 Million

Avg. Volume

405.05 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.85-6.4
PE
-
EPS
-
Beta Value
1.786
ISIN
US9013841070
CUSIP
901384107
CIK
1860782
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. William D. Baird III, M.B.A.
Employee Count
-
Website
https://www.2seventybio.com
Ipo Date
2021-11-03
Details
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.